James Hoekstra to Peptide Fragments
This is a "connection" page, showing publications James Hoekstra has written about Peptide Fragments.
Connection Strength
0.409
-
Geisler T, Droppa M, Gawaz M, Steinhubl SR, Bertrand ME, Lincoff AM, Cequier AR, Desmet W, Rasmussen LH, Hoekstra JW, Bernstein D, Deliargyris EN, Mehran R, Stone GW. Impact of anticoagulation regimen prior to revascularization in patients with non-ST-segment elevation acute coronary syndromes: The ACUITY trial. Catheter Cardiovasc Interv. 2016 Aug; 88(2):174-81.
Score: 0.104
-
Miller CD, Blomkalns AL, Gersh BJ, Pollack CV, Brogan GX, Diercks DB, Peacock WF, Stone GW, Hollander JE, Manoukian SV, Hoekstra JW. Safety and efficacy of bivalirudin in high-risk patients admitted through the emergency department. Acad Emerg Med. 2009 Aug; 16(8):717-25.
Score: 0.068
-
Hoekstra J, Cohen M, Giugliano R, Granger CB, Gurbel PA, Hollander JE, Manoukian SV, Saucedo JF, Pollack CV. Expert consensus on treatment strategies in non- ST-segment elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention--an evidence-based review of clinical trial results and treatment guidelines from an emergency medicine perspective: report on a roundtable discussion. Am J Emerg Med. 2009 Jul; 27(6):720-8.
Score: 0.068
-
White HD, Chew DP, Hoekstra JW, Miller CD, Pollack CV, Feit F, Lincoff AM, Bertrand M, Pocock S, Ware J, Ohman EM, Mehran R, Stone GW. Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. J Am Coll Cardiol. 2008 May 06; 51(18):1734-41.
Score: 0.062
-
Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, White HD, Pocock SJ, Ware JH, Feit F, Colombo A, Aylward PE, Cequier AR, Darius H, Desmet W, Ebrahimi R, Hamon M, Rasmussen LH, Rupprecht HJ, Hoekstra J, Mehran R, Ohman EM. Bivalirudin for patients with acute coronary syndromes. N Engl J Med. 2006 Nov 23; 355(21):2203-16.
Score: 0.056
-
Diercks DB, Pollack CV, Hollander JE, Blomkalns AL, Emerman CL, Rokos IC, Larson DM, Hoekstra JW, Mehran R, Stone GW. The time dependence of antithrombin initiation in patients with non-ST-segment elevation acute coronary syndromes: subgroup analysis from the ACUITY trial. Ann Emerg Med. 2011 Mar; 57(3):204-212.e1-6.
Score: 0.018
-
Lopes RD, Alexander KP, Manoukian SV, Bertrand ME, Feit F, White HD, Pollack CV, Hoekstra J, Gersh BJ, Stone GW, Ohman EM. Advanced age, antithrombotic strategy, and bleeding in non-ST-segment elevation acute coronary syndromes: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. J Am Coll Cardiol. 2009 Mar 24; 53(12):1021-30.
Score: 0.017
-
Cohen M, Hoekstra J, Giugliano R, Granger CB, Gurbel PA, Hollander JE, Manoukian SV, Pollack CV, Saucedo JF. Treatment strategies in non-ST-elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention: an evidence-based review of clinical trial results and treatment guidelines: report on a roundtable discussion. J Interv Cardiol. 2008 Aug; 21(4):283-99.
Score: 0.016